key: cord-0795856-07b2uaq7
authors: Le, Nicole K.; Brooks, Joel P.
title: Acute urticaria as the initial presentation of COVID-19 in a pediatric patient
date: 2021-03-16
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.03.001
sha: 8cec4b4f6616cc9cd4f15e0a85d10cddb45f5c6f
doc_id: 795856
cord_uid: 07b2uaq7

nan

presenting symptoms of COVID-19 include fever, chills, cough, shortness of breath, fatigue, 26 myalgia, headache, ageusia, and anosmia. [5, 6] We report a pediatric patient whose initial 27 presenting symptom of COVID-19 was acute urticaria.

A five-year-old Hispanic female with no significant medical history was seen for evaluation of 30 acute urticaria. Approximately one month previously, the patient developed hives after returning 31 home from her father's house where she spent the weekend. Her initial symptoms were hives 32 across her entire body, sparing her face ( Figure 1 ). She was treated with oral and topical 33 diphenhydramine at the recommendation of her pediatrician. Her hives were moderately pruritic 34 and worsened after she showered. Two days after her hives began, she developed fevers with her 35 temperature reaching 101.6°F. Her fever was treated with acetaminophen but continued to 36 persist, along with her hives, for the next three days.

As her symptoms continued to worsen, she presented to the emergency department five days 38 after her symptoms began but was treated for idiopathic urticaria with H1 blockade and 39 discharged home. Two days later she developed a cough. She returned to the emergency 40 J o u r n a l P r e -p r o o f department 11 days after her initial presentation due to her persistent hives, fevers, and cough.

Her severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR test was positive, and 42 she underwent additional evaluation for COVID-19 (Table 1 ). Her prothrombin time was 14.1, 43 INR was 1.08, activated partial thromboplastin time was 36, fibrinogen was 329, and D-dimer 44 was 0.75. In addition, her CRP was 1.08, troponin was <0.02, ferritin was 88, and N-terminal 45 brain natriuretic peptide was 25. As she was clinically stable, the patient was discharged home 46 with supportive care. She continued to receive acetaminophen and was transitioned to cetirizine 47 instead of diphenhydramine. Her symptoms persisted for the following week before resolving 48 and have not reoccurred.

It was later determined that the patient's father was ill with COVID-19 when she stayed with him 50 the weekend prior to developing urticaria. Over the course of the 11 days prior to her COVID-19 51 diagnosis, several immediate and extended family members developed COVID-19 infections 52 which were eventually traced back to exposure to the patient. She presented for follow up to an 53 outpatient allergy practice for further evaluation of her acute urticaria. As she was now Figure 

Urticaria and infections

Cutaneous manifestations in COVID-19: a first perspective

Cutaneous manifestations in 86 patients with COVID-19: a preliminary review of an emerging issue

Classification of the cutaneous manifestations of COVID-92 19: a rapid prospective nationwide consensus study in Spain with 375 cases

96 Clinical features of patients infected with 2019 novel coronavirus in

are early indicators of the COVID-19 pandemic and political decision effectiveness

Cutaneous Manifestations of COVID-19: An Evidence-Based 104

COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-107

Are erythema multiforme and urticaria related to a 109 better outcome of COVID-19?

Association 111 between urticaria and virus infections: A systematic review